TITLE:
Initial Analysis of Lipid Metabolomic Profile Reveals Differential Expression Features in Myeloid Malignancies
AUTHORS:
Adriana Ramos de Oliveira, Ismael Dale Cotrim Guerreiro Da Silva, Edson G. Lo Turco, Helio Alves Martins Júnior, Maria de Lourdes L. Ferrari Chauffaille Chauffaille
KEYWORDS:
Lipids, Lipidomics, Myeloproliferative Neoplasms, Mass Spectrometry
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.15,
December
25,
2015
ABSTRACT: The purpose of this preliminary study was to determine the comparative
lipid profile of blood plasma samples of healthy individuals and patients with
Myeloproliferative Neoplasms. Methods: Untargeted Shotgun MS/MS Analysis was
performed to evaluate plasma samples from 153 participants, being 90 of the
Control Group, 43 Myeloproliferative Neoplasms (MPN), 11 Myelodysplastic
Syndromes (MDS) and 9 Acute Myeloid Leukemias (AML). Lipids were extracted from
plasma using the Bligh-Dyer protocol. Data were acquired using the AB-Sciex
Analyst TF, processed using the AB-Sciex LipidViewTM and the web-based analytical pipeline MetaboAnalyst
2.0 (www.metaboanalyst.ca). Results: Untargeted analysis identified in
negative and positive-modes a total of 658 features at 2 ppm resolution. PCA
and PLS-DA analysis revealed clear discrimination among groups, in particular
for AML patients. Main lipid groups differentially expressed were:
Monoacylglycerols (MAG), Glucosylceramide E (GlcdE), Ethyl Esters (EE),
Lysophosphatidic acid (LPA), Sulfoquinovosil diacylglycerols (SQDG),
Monoglycerols (MG), Methyl Ethanolamines (ME), Lysophosphatidylcholines (LPC), Dimethyl
Phosfatidyletanolamines (DMPE), Monometylphosphatidiletanolamines (MMPE), Ceramide-1-phosphate (CerP), Glicerophosphoglycerols (GP), Lysomonomethyl-Phosphatidylethanolamines (LMMPE), Phosphatidic
Acids (PA), Ergosterols (ERG), Glycerophosphoserine (PS), Diacylglycerols
(DAG), Hexocylceramides (HexCer) and Lanosterol (Lan). ROC Curve Analysis
revealed Total LMMPE as the strongest discriminating marker between Controls
from Patients. In addition, these lipids were also able to differentiate MDS
and AML from NPM. Conclusions: The Myeloproliferative Neoplasms from the point
of view of global plasma lipidomics are accompanied by several modifications.
In particular, the Lysomonomethyl-Phosphatidylethanolamines (LMMPE) seems to
play important differentiating roles among them.